Back


19/06/2017
Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
Zealand Pharma ("Zealand") announces positive results from the Phase 2 trial of glepaglutide in adult patients with short bowel syndrome (SBS). Glepaglutide is a novel long-acting GLP-2 analogue invented and fully owned by Zealand. [...]

Download the pdf file





X

X